(1923 - 2001)
Médico oftalmólogo. Notable científico, conocido internacionalmente por haber concebido un nuevo tratamiento para la retinosis pigmentaria.
Biomedical Sciences
2003 | Vax-SPIRAL: Antileptospirosis trivalent vaccine in humans, research, development and impact on the desease in Cuba.
Main author: Marta González González, Raydel Martínez Sánchez, Raúl Crúz de la Paz.
Coauthors: Juan Francisco Infante Boursac, Irma Estela González Novo, Idalia Morelia Baró Suárez, Alberto Pérez Sierra, Gustavo Sierra González, Omar Figueredo Rodríguez,  Raúl Boué Gutiérrez, Jorge Menéndez Hernández, Yoandra Rodríguez Jiménez, Reynaldo Oliva Hernández, Marlene Isabel Martínez del Rio, Angel Manuel Alvarez, Reynaldo Menéndez Capote, Manuel Díaz González, Carmen Fernández Molina, José Enrique Rodríguez Silveira, Luis Izquierdo Pérez, Rolando Ochoa Arce, Ana Margarita Obregón Fuentes, Esther Maria Fajardo, Lilia Alfalla Valdés, Mariela Naranjo Medina, Niurka Batista Santiesteban, Caridad Torres Suárez, Sonia Padrón Padrón, Francisco Domínguez Alvarez, Ramón Barberá Morales, Concepción Campa Huergo

This work undertook the full-cycle development of a antileptospirosis vaccine considers the following contributions: vaccine:

Nowadays, only one vaccine, a french one from Pasteur Merieux (Spirolet) for a serovar (L. icterohaemorrhagiae), can be found in the market. Ours is a trivalent vaccine (canicola, copenhageni,mozdok),making possible, as far as technology permits, to develop a modular treatment including or leaving out certain serovars.

  • This is the first antileptospirosis vaccine reported which develops phase IV clinical studies with clinical effectiveness in thousands of volunteers.
  • The vaccine is safe and not so reactogenic since it presents, in 2 142 709 vaccinated persons, a reduction of a 81.2% of morbility and a 32.7% of mortality. Serogroup effectiveness is 778.1%.
  • Aproved by theState Center for Drugs (CECMED), it is included in the National Program for Leptospirosis Prevention and Control.
  • The concept of adjuvating and stabilizating with aluminium hydroxide is novel and unique in this type of vaccine.
  • An animal model was developed in golden Syrian hamster favoring a considerable volume of preclinical information, being a highly predictive model.
  • It has 14 published articles in Cuba and abroad.